GLOBAL BIO-CHEM (00809): Completion of Boiler Renovation Project and Commencement of Civil Engineering Works for Coenzyme Q10 Project

GLOBAL BIO-CHEM (00809) announced the signing of an EPC contract for a boiler renovation project and a cooperation agreement between its indirect wholly-owned subsidiary DACHENG DAHAO and Shenzhou Biotechnology Co., Ltd. (Shenzhou Biotechnology) to produce coenzyme Q10 mycelium (Coenzyme Q10 project). On August 31, 2026, the completion and ignition ceremony of the boiler renovation project, along with the formal launch ceremony for the civil engineering of the Coenzyme Q10 project, were successfully held at the Groups production base in Dehui, Jilin Province, China. Representatives from local government departments, Jilin Provincial Agricultural Investment Group Co., Ltd., project construction contractors, and several major financial institutions including Shanghai Pudong Development Bank Changchun Branch, Jilin Rural Commercial Bank Changchun Regional Branch, Jilin Bank Changchun Branch, CEB BANK Changchun Branch, and Industrial Bank Economic Development Branch were invited to attend the ceremony and witness the official production launch of the renovated and upgraded boiler and the commencement of the Coenzyme Q10 projects civil works. As disclosed in the boiler EPC announcement, the boiler renovation project is the Groups flagship project, showcasing the application of high-temperature/high-pressure and ultra-high-temperature/ultra-high-pressure boilers deployed at the Dehui production base. It aims to achieve greater energy cost efficiency while supporting the Groups overall sustainable development. The boiler renovation project has been successfully completed and officially commenced production, and it is expected to significantly optimize operational efficiency, enhance cost competitiveness, and lay a solid foundation for the Groups long-term growth. Furthermore, the civil engineering for the Coenzyme Q10 project at the Dehui production base officially commenced on August 31, 2026. The implementation of the Coenzyme Q10 project marks an important milestone for the Group as it ventures into the field of synthetic biology and expands into the healthcare and medical applications market. After full completion and commercialization, this project will refine the Group's business layout, enhance operational efficiency, and drive high-quality growth across various business segments. In addition, it will support the strategic shift of the Groups product portfolio towards higher-margin bioconversion products, enabling the Group to better cope with market fluctuations and maintain long-term stability.